Please assess the completion status of the following clinical trial:

Trial Title: Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least a 6 month history of physician diagnosed migraine and typically experiences 2-6 migraine attacks per month~* Typically experiences moderate to severe migraine pain preceded by a mild pain phase~* Differentiate between mild migraine pain and other headache types~* Women of childbearing potential must be on adequate contraception~Exclusion Criteria:~* Pregnant and/or nursing mother~* History of cardiovascular disease~* Uncontrolled hypertension~* Basilar or Hemiplegic migraine~* History of stroke or transient ischemic attacks (TIA)~* History of epilepsy or treated with anti-epileptics within past 5 years~* Impaired hepatic or renal function~* History of gastrointestinal bleeding or ulceration~* Allergy or hypersensitivity to aspirin or any other NSAID~* Allergy or hypersensitivity to triptans~* Participated in an investigational drug trial in the previous 4 weeks

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).